Orthofix International N.V. (OFIX) Earning Somewhat Positive Media Coverage, Analysis Finds
Press coverage about Orthofix International N.V. (NASDAQ:OFIX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Orthofix International N.V. earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave headlines about the medical device company an impact score of 44.6717328626859 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- $0.41 EPS Expected for Orthofix International N.V. (OFIX) This Quarter (americanbankingnews.com)
- Orthofix International N.V. (OFIX) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- Global bone growth stimulators market is estimated to reach USD 1.32 billion by 2021 according to new research report (whatech.com)
- Orthofix (OFIX) is a Great Momentum Pick for You: Here’s Why (zacks.com)
- Orthofix (OFIX) is a Great Momentum Pick for You: Here's Why (finance.yahoo.com)
A number of brokerages recently commented on OFIX. Zacks Investment Research downgraded Orthofix International N.V. from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Langenberg & Company restated a “buy” rating and set a $53.25 price objective on shares of Orthofix International N.V. in a research note on Wednesday, June 14th. Jefferies Group LLC restated a “buy” rating and set a $55.00 price objective (up from $50.00) on shares of Orthofix International N.V. in a research note on Thursday, August 10th. BidaskClub downgraded Orthofix International N.V. from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, BTIG Research initiated coverage on Orthofix International N.V. in a research report on Wednesday, June 21st. They set a “buy” rating and a $52.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average price target of $52.75.
Shares of Orthofix International N.V. (NASDAQ:OFIX) opened at 48.13 on Thursday. Orthofix International N.V. has a one year low of $32.51 and a one year high of $49.60. The stock has a 50 day moving average price of $46.23 and a 200 day moving average price of $41.75. The firm has a market cap of $874.52 million, a price-to-earnings ratio of 112.72 and a beta of 0.25.
Orthofix International N.V. (NASDAQ:OFIX) last posted its quarterly earnings data on Monday, August 7th. The medical device company reported $0.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.01. The business had revenue of $108.90 million during the quarter, compared to the consensus estimate of $102.94 million. Orthofix International N.V. had a return on equity of 9.96% and a net margin of 1.88%. Orthofix International N.V.’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.41 earnings per share. On average, equities research analysts forecast that Orthofix International N.V. will post $1.57 EPS for the current year.
In other Orthofix International N.V. news, insider Raymond Fujikawa sold 6,364 shares of the stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $47.06, for a total transaction of $299,489.84. Following the completion of the sale, the insider now directly owns 31,084 shares in the company, valued at approximately $1,462,813.04. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Brad Mason sold 2,733 shares of the stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $48.10, for a total value of $131,457.30. Following the sale, the chief executive officer now owns 188,053 shares of the company’s stock, valued at $9,045,349.30. The disclosure for this sale can be found here. Company insiders own 5.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Orthofix International N.V. (OFIX) Earning Somewhat Positive Media Coverage, Analysis Finds” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/31/orthofix-international-n-v-ofix-earning-somewhat-positive-media-coverage-analysis-finds.html.
Orthofix International N.V. Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Stock Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related stocks with our FREE daily email newsletter.